|Bid||161.00 x 900|
|Ask||175.50 x 800|
|Day's Range||168.49 - 170.78|
|52 Week Range||118.64 - 170.78|
|Beta (5Y Monthly)||1.13|
|PE Ratio (TTM)||50.82|
|Earnings Date||Feb 18, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Nov 21, 2012|
|1y Target Est||177.20|
Cloud computing play Paycom stock leads four top stocks to consider for the long-term. Fiserv stock, UNH stock and Masimo stock also make the list. Here's why.
Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. We'll look at Masimo...
Masimo Corporation (NASDAQ: MASI) today announced select preliminary results for the full-year ended December 28, 2019 and provided estimates for its full-year 2020 financial guidance.
Masimo and NantHealth announced the signing of a definitive agreement under which Masimo will acquire the Connected Care assets from NantHealth.
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged in 2019. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 57%. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. That's why we weren't […]
(Bloomberg) -- Apple Inc. is accused of stealing trade secrets and improperly using Masimo Corp. inventions related to health monitoring in its Apple Watch.Masimo, which develops signal processing technology for health-care monitors, and its spinoff, Cercacor Laboratories Inc., claim in a lawsuit that Apple got secret information under the guise of a working relationship and then hired away key employees, including Michael O’Reilly, who became vice president of Apple’s health technology efforts.The business segment that includes the Apple Watch, Apple TV and Beats headphones is the company’s fastest-growing category and generated more than $24 billion in sales in the fiscal year that ended in September.Masimo and Cercacor said their technology for non-invasive monitoring using light was key to Apple overcoming performance issues with its Watch. Among the 10 patents Apple is accused of infringing are ones covering ways to measure oxygen levels in blood, and heart rate using light emitters and detectors.The companies are seeking orders that would block further use of their patented inventions in the Apple Watch 4 and 5, return of confidential information and unspecified damages.Officials with Cupertino, California-based Apple didn’t immediately return queries seeking comment.Apple contacted Masimo in 2013 and asked to meet for a potential collaboration, according to the complaint filed in federal court in Santa Ana, California. Apple said it wanted “to understand more about Masimo’s technology to potentially integrate that technology into Apple’s products,” Masimo said.After what Masimo thought were productive meetings, Apple instead hired O’Reilly, who was then Masimo’s chief medical officer and was “privy to extremely sensitive information,” according to the suit.The next year, it hired Marcelo Lamego, who was Cercacor’s chief technology officer and a former Masimo scientist. Lamego had “unfettered access” to confidential technical information and, shortly after starting work at Apple, began pursuing patent applications for things that he learned at the companies. Apple knew it was getting confidential information from the two men, the companies said.“Given what appeared to be a targeted effort to obtain information and expertise from Masimo and Cercacor, Masimo and Cercacor warned Apple about respecting their rights,” the companies said in the complaint.Neither man was named as a defendant in the suit.Read more on another Watch lawsuitMasimo and Cercacor also are seeking to add their engineers to seven patents and applications that were issued to Lemego. That would make Masimo and Cercacor owners, or at least joint owners, of those patents and applications currently assigned to Apple.It’s not the first time that Apple’s faced allegations of strong-arming information from companies that thought they were working with the tech giant. In October, it was accused of stealing patented technology from an email developer and then removing the man’s messaging service from its App Store so it wouldn’t be a competitor.Apple has also been accused of incorporating another’s patented invention into its Watch without paying. Last month, a New York cardiologist filed a lawsuit saying Apple owes him royalties on the Watch feature that provides notifications of an irregular heartbeat.The case is Masimo Corp. v. Apple Inc., 20-48, U.S. District Court for the Central District of California (Santa Ana).(Updates with O’Reilly in second paragraph.)To contact the reporters on this story: Susan Decker in Washington at email@example.com;Mark Gurman in Los Angeles at firstname.lastname@example.orgTo contact the editors responsible for this story: Jon Morgan at email@example.com, Joe SchneiderFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Masimo (MASI) will cater to the whole prenatal patient population, with the recent FDA clearance within the SET pulse oximetry business.
Masimo RD SET® sensors for neonatal patients have received FDA clearance for improved SpO2 accuracy specifications.
Masimo and Dräger are expanding their licensing agreement to add Masimo SedLine®, O3®, and NomoLine® to Dräger patient monitors.
In this article, I will take a look at Masimo Corporation's (NasdaqGS:MASI) most recent earnings update (28 September...
A multicenter study evaluated the trend accuracy of three hemoglobin monitoring methods, including noninvasive Masimo SpHb® and two invasive methods.
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]
Masimo today announced that its management is scheduled to present at the Evercore ISI 2nd Annual HealthCONx Conference at the Four Seasons Boston Hotel on Thursday, December 5, 2019 at 11:00 a.m.
Masimo (NASDAQ: MASI) today announced that its management is scheduled to present at the Piper Jaffray 31st Annual Healthcare Conference at the Lotte New York Palace Hotel on Wednesday, December 4, 2019 at 9:30 a.m. Eastern Time. A live audiocast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the audiocast will be available following the live presentation.
Digital health is committed to changing the face of healthcare as evident from its innovative solutions for the betterment of patients' lives.
Masimo announced today that in a study recently published in the Journal of Clinical Monitoring and Computing, researchers at Nippon Medical School in Tokyo, Japan u
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Masimo today announced that its management is scheduled to present at the Stifel 2019 Healthcare Conference at the Lotte New York Palace Hotel on Tuesday, November 19, 2019 at 10:55 a.m.